Silenor (Doxepin HCl) Patent Expiration, LOE Window & CMS Spending
Silenor (Doxepin HCl) by Currax: FDA Orange Book LOE 2030-09-07, 8 AB generics, $504K 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Currax |
| FDA Application & Pathway | N022036 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2030-09-07 |
| Orange Book Patents (*PED Extensions) | 16 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 8 |
| 2024 CMS Total Public Spend | $504K |
| 2024 Medicare Part D Spend | $504K |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |